Blueprint Medicines(BPMC) - 2023 Q3 - Earnings Call Presentation

Third Quarter 2023 Financial Results Not for promotional use Agenda AYVAKIT PERFORMANCE Q3 2023 FINANCIAL PERFORMANCE Kate Haviland Chief Executive Officer Christy Rossi Chief Operating Officer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidate ...